作为用于治疗癌症的CD73抑制剂的新型双环杂环化合物。
Novel Bicyclic Heterocyclic Compounds as CD73 Inhibitors for Treating Cancer.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2024 Dec 4;16(1):10-11. doi: 10.1021/acsmedchemlett.4c00565. eCollection 2025 Jan 9.
Abstract
Provided herein are novel bicyclic heterocyclic compounds as CD73 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.
摘要
本文提供了作为CD73抑制剂的新型双环杂环化合物、药物组合物、此类化合物在治疗癌症中的用途以及制备此类化合物的方法。
相似文献
1
Novel Bicyclic Heterocyclic Compounds as CD73 Inhibitors for Treating Cancer.作为用于治疗癌症的CD73抑制剂的新型双环杂环化合物。
ACS Med Chem Lett. 2024 Dec 4;16(1):10-11. doi: 10.1021/acsmedchemlett.4c00565. eCollection 2025 Jan 9.
2
Bicyclic Ureas as JAK2 Inhibitors for Treating Hematological Cancer.双环脲类化合物作为治疗血液系统癌症的JAK2抑制剂
ACS Med Chem Lett. 2024 Oct 29;15(11):1824-1825. doi: 10.1021/acsmedchemlett.4c00496. eCollection 2024 Nov 14.
3
Novel Heterocyclic Compounds as Monoacylglycerol Lipase Inhibitors for Treating Multiple Diseases.作为用于治疗多种疾病的单酰甘油脂肪酶抑制剂的新型杂环化合物。
ACS Med Chem Lett. 2024 Jun 21;15(7):994-995. doi: 10.1021/acsmedchemlett.4c00261. eCollection 2024 Jul 11.
4
Novel Bicyclic Heterocycles as MRGPRX2 Antagonists for Treating Inflammatory Diseases.新型双环杂环化合物作为治疗炎症性疾病的MRGPRX2拮抗剂
ACS Med Chem Lett. 2025 Jun 2;16(6):980-981. doi: 10.1021/acsmedchemlett.5c00305. eCollection 2025 Jun 12.
5
Novel Compounds as CDK2 Inhibitors for Treating Cancer.新型化合物作为治疗癌症的CDK2抑制剂
ACS Med Chem Lett. 2024 Dec 10;16(1):14-15. doi: 10.1021/acsmedchemlett.4c00574. eCollection 2025 Jan 9.
6
Pyrrolopyrazine Compounds as ERK5 Inhibitors for Treating Cancer.作为用于治疗癌症的细胞外信号调节激酶5（ERK5）抑制剂的吡咯并吡嗪化合物
ACS Med Chem Lett. 2024 Dec 11;16(1):16-17. doi: 10.1021/acsmedchemlett.4c00580. eCollection 2025 Jan 9.
7
Novel Indazole Compounds as PKMYT1 Kinase Inhibitors for Treating Cancer.新型吲唑化合物作为治疗癌症的PKMYT1激酶抑制剂
ACS Med Chem Lett. 2024 Oct 12;15(11):1810-1811. doi: 10.1021/acsmedchemlett.4c00486. eCollection 2024 Nov 14.
8
Novel Compounds as NLRP3 Inhibitors for Treating Cardiovascular Diseases.作为治疗心血管疾病的NLRP3抑制剂的新型化合物。
ACS Med Chem Lett. 2024 Jul 11;15(8):1184-1185. doi: 10.1021/acsmedchemlett.4c00304. eCollection 2024 Aug 8.
9
Novel Phenylpiperidine Derivatives as QPCT and QPCTL Inhibitors for Treating Cancer or Fibrotic Diseases.新型苯基哌啶衍生物作为QPCT和QPCTL抑制剂用于治疗癌症或纤维化疾病。
ACS Med Chem Lett. 2024 Oct 30;15(11):1826-1827. doi: 10.1021/acsmedchemlett.4c00495. eCollection 2024 Nov 14.
10
Novel Cyanopyridine Compounds as KHK Inhibitors for Treating NAFLD, NASH, and Type II Diabetes.新型氰基吡啶化合物作为治疗非酒精性脂肪性肝病、非酒精性脂肪性肝炎和II型糖尿病的KHK抑制剂
ACS Med Chem Lett. 2024 Jul 23;15(8):1191-1192. doi: 10.1021/acsmedchemlett.4c00332. eCollection 2024 Aug 8.
本文引用的文献
1
Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions.免疫检查点抑制剂在非小细胞肺癌中的重挑战：当前证据和未来方向。
Cancer Lett. 2024 Nov 1;604:217241. doi: 10.1016/j.canlet.2024.217241. Epub 2024 Sep 10.
2
Potential mechanisms of cancer stem-like progenitor T-cell bio-behaviours.癌症干细胞样祖细胞 T 细胞生物行为的潜在机制。
Clin Transl Med. 2024 Aug;14(8):e1817. doi: 10.1002/ctm2.1817.
3
Regulation of CD73 on NAD metabolism: Unravelling the interplay between tumour immunity and tumour metabolism.CD73 对 NAD 代谢的调控：揭示肿瘤免疫与肿瘤代谢之间的相互作用。
Cell Commun Signal. 2024 Aug 1;22(1):387. doi: 10.1186/s12964-024-01755-y.
4
Novel Heteroaryl Compounds as CD73 Inhibitors for Treating Cancer.新型杂芳基化合物作为用于治疗癌症的CD73抑制剂
ACS Med Chem Lett. 2024 May 31;15(6):775-776. doi: 10.1021/acsmedchemlett.4c00230. eCollection 2024 Jun 13.
5
Metabolic interplay: tumor macrophages and regulatory T cells.代谢相互作用：肿瘤巨噬细胞和调节性 T 细胞。
Trends Cancer. 2024 Mar;10(3):242-255. doi: 10.1016/j.trecan.2023.11.007. Epub 2023 Dec 22.
6
Small molecular CD73 inhibitors: Recent progress and future perspectives.小分子 CD73 抑制剂：最新进展与未来展望。
Eur J Med Chem. 2024 Jan 15;264:116028. doi: 10.1016/j.ejmech.2023.116028. Epub 2023 Dec 7.
Zotero 插件